a study of experimental medication bms-986251, taken by mouth, in healthy participants and patients with average to very serious psoriasis

Conditions: Rheumatoid Arthritis; Psoriasis; Ankylosing Spondylitis; Inflammatory Bowel Diseases; Nonalcoholic Steatohepatitis

Summary: the purpose of this study is to investigate experimental medication bms-986251 taken by mouth in healthy patients and patients with average to very serious psoriasis (a condition characterized by itchy, dry skin with a scaly rash).


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria (healthy patients): * males and females, ages 18 to 55 years, inclusive, at screening * healthy subjects, as determined by no clinically significant deviations from normal in medical history, physical examination, 12-lead ecgs, vital signs, and clinical laboratory results * body mass index (bmi) of 18.0 to 30.0 kg/m2, inclusive, at screening * body weight between 55 kg and 105 kg, inclusive, at screening * women must not be breastfeeding exclusion criteria (healthy patients): * previous participation in the current study * participation in a drug study or exposure to any investigational drug or placebo within 2 months prior to (the first) drug administration in the current study * employees of pra or the sponsor and their relatives * any significant acute or chronic medical condition that presents a potential risk to the subject and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome * current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect pharmacokinetics; history of cholecystectomy is not allowed inclusion criteria (psoriasis patients): * males and females, ages 18 to 70 years, inclusive, at screening * bmi of 18.0 to 35.0 kg/m2, inclusive, at screening * body weight between 55 kg and 120 kg, inclusive, at screening * diagnosed with stable chronic plaque psoriasis, for at least 6 months prior to screening and be candidates for either photo-therapy or systemic treatment * moderate-to-severe intensity of psoriasis as defined by: 1. affected body surface area (bsa) of ≥10% 2. psoriasis area and severity index (pasi) ≥12 3. physician global assessment (pga; 6-point scale) ≥3 exclusion criteria (psoriasis patients): * previous participation in the current study * participation in a drug study or exposure to any investigational drug or placebo within 2 months prior to (the first) drug administration in the current study * employees of pra or the sponsor and their relatives * any significant acute or chronic medical condition that presents a potential risk to the subject and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome * current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect pharmacokinetics; history of cholecystectomy is not allowed other protocol defined inclusion/exclusion criteria could apply